Antimicrobial susceptibility of clinical isolates collected from sites in central Europe in 2019 was tested by CLSI broth microdilution method and EUCAST breakpoints. Most active were amikacin, ceftazidime-avibactam and colistin; respectively, susceptibility rates among P. aeruginosa (n = 701) were 89.2%, 92.2% and 99.9%; difficult-to-treat (DTR) isolates, 62.5%, 37.5% and 100%; multidrug-resistant (MDR) isolates, 68.3%, 72.9% and 99.5%; meropenem-resistant (MEM-R), metallo-β-lactamase-negative (MBL-negative) isolates, 72.8%, 78.6% and 100%. Among Enterobacterales (n = 1639), susceptibility to ceftazidime-avibactam, colistin and tigecycline was ≥ 97.9%; MDR Enterobacterales, 96.8%, 94.4% and 100%, respectively; DTR isolates, ≥ 76.2% to ceftazidime-avibactam and colistin; MEM-R, MBL-negative isolates, ≥ 90.0% to ceftazidime-avibactam and colistin.

Department of Clinical and Molecular Microbiology University Hospital Centre Zagreb Zagreb Croatia

Department of Medical Microbiology Faculty of Medicine University of Debrecen Debrecen Hungary

Department of Microbiology University Hospital Cracow Poland

Institute of Medical Biochemistry and Laboratory Diagnostics General University Hospital Prague Czech Republic

Pfizer Croatia Zagreb Croatia

Pfizer Export B 5 RO Kyiv Ukraine

Pfizer Polska Sp z o o Warsaw Poland

Pfizer spol s r o Prague Czech Republic

Zobrazit více v PubMed

Pang Z, Raudonis R, Glick BR, Lin T-J, Zhenyu Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37:177–192. doi: 10.1016/j.biotechadv.2018.11.013. PubMed DOI

De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, Paterson DL, Walker MJ. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev. 2020;33:e00181–19. doi: 10.1128/CMR.00181-19. PubMed DOI PMC

de Jonge BLM, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study. Antimicrob Agents Chemother. 2016;60:3163–3169. doi: 10.1128/AAC.03042-15. PubMed DOI PMC

Levasseur P, Girard AM, Miossec C, Pace J, Coleman K. In vitro antibacterial activity of the ceftazidime-avibactam combination against Enterobacteriaceae, including strains with well-characterized β-lactamases. Antimicrob Agents Chemother. 2015;59:1931–1934. doi: 10.1128/AAC.04218-14. PubMed DOI PMC

Papp-Wallace KM, Bajaksouzian S, Abdelhamed AM, Foster AN, Winkler ML, Gatta JA, Nichols WW, Testa R, Bonomo RA, Jacobs MR. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases. Diagn Microbiol Infect Dis. 2015;82:65–69. doi: 10.1016/j.diagmicrobio.2015.02.003. PubMed DOI PMC

Clinical and Laboratory Standards Institute (2018) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards. 11th ed. CLSI document M07. Wayne, PA: Clinical and Laboratory Standards Institute

The European Committee on Antimicrobial Susceptibility Testing (2021) Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0. http://www.eucast.org. Accessed 3 Aug 2021

Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, Sahm DF. Trends in susceptibility of Escherichia coli from intra-abdominal infections to and comparators in the United States according to data from the SMART program, 2009–2013. Antimicrob Agents Chemother. 2015;59:3606–3610. doi: 10.1128/AAC.05186-14. PubMed DOI PMC

Nichols WW, de Jonge BLM, Kazmierczak KM, Karlowsky JA, Sahm DF. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014) Antimicrob Agents Chemother. 2016;60:4743–4749. doi: 10.1128/AAC.00220-16. PubMed DOI PMC

Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15. J Antimicrob Chemother. 2018;73:2777–2781. doi: 10.1093/jac/dky267. PubMed DOI

Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012–15. J Antimicrob Chemother. 2018;73:2782–2788. doi: 10.1093/jac/dky266. PubMed DOI

Kristóf K, Adámková V, Adler A, Gospodarek-Komkowska E, Rafila A, Billová S, Możejko-Pastewka B, Kiss F. In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014–2017 and 2018. Diagn Microbiol Infect Dis. 2021;101:115420. doi: 10.1016/j.diagmicrobio.2021.115420. PubMed DOI

Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, Powers 3rd JH, Suffredini AF, Hooper DC, Fridkin S, Danner RL, National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI) (2018) Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis 67:1803–1814. 10.1093/cid/ciy378 PubMed PMC

Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16:661–673. doi: 10.1016/S1473-3099(16)30004-4. PubMed DOI

Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62:1380–1389. doi: 10.1093/cid/ciw133. PubMed DOI PMC

Torres A, Zhong N, Pachl J, Timsit J-F, Kollef M, Chen Z, Song J, Taylor D, Laud PJ, Stone GG, Chow JW. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285–295. doi: 10.1016/S1473-3099(17)30747-8. PubMed DOI

Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;63:754–762. doi: 10.1093/cid/ciw378. PubMed DOI PMC

In vitro activity of antibiotics potentially effective against difficult-to-treat strains of Gram-negative rods: retrospective study